6CM
IMNM icon

683 Capital Management’s Immunome IMNM Stock Holding History

683 Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,149
Closed -$290K – 194
2023
Q4 		$290K Buy
+27,149
New +$226K 0.02% 124

Other funds holding IMNM

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

683 Capital Management's IMNM Position: Q1 2024 in Review

683 Capital Management sold out of Immunome (IMNM) in Q1 2024, closing a stake of 27,149 shares — an estimated $290K sold.

683 Capital Management first reported a position in IMNM in Q4 2023 and held it in 1 quarter. The position peaked at $290K in Q4 2023. 104 funds tracked by Wall St. Rank hold IMNM as of Q1 2024.

  • 683 Capital Management reported no remaining Immunome position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 27,149 Immunome shares in Q1 2024, an estimated $290K.
  • 683 Capital Management first reported a position in Immunome in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Immunome position peaked at $290K in Q4 2023.
  • 104 funds tracked by Wall St. Rank held Immunome as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.